Adrenocorticotropic hormone in the prevention of cisplatin-induced nausea and vomiting.

1983 ◽  
Vol 1 (10) ◽  
pp. 635-639 ◽  
Author(s):  
N Colbert ◽  
V Izrael ◽  
J P Lotz ◽  
D Stoppa-Lyonnet ◽  
J M Vannetzel ◽  
...  

A double-blind trial to evaluate the antiemetic effects of adrenocorticotropic hormone (ACTH) in patients treated with cisplatin was performed. Thirty-seven adults with advanced cancer who were treated with cisplatin were randomly assigned to receive either synthetic long-acting ACTH (1 mg IM given 24 hours, 12 hours, and immediately preceding the administration of cisplatin) or a placebo given under the same conditions. All of the patients received chlorpromazine (50 mg IM) 30 minutes before cisplatin infusion. Patients receiving ACTH and chlorpromazine had significantly fewer episodes of vomiting (p less than 0.01) and shorter periods of nausea (p less than 0.02) than patients receiving placebo and chlorpromazine. Patients receiving ACTH and chlorpromazine were significantly more comfortable than patients receiving placebo and chlorpromazine. No important side effects were observed. ACTH may be an effective agent in preventing nausea and vomiting induced by cisplatin.

1973 ◽  
Vol 1 (4) ◽  
pp. 308-314 ◽  
Author(s):  
David B. Gibb ◽  
Nicholas Pikler

Piritramide is a synthetic analgesic of the piperidine group. Reports indicate that it is a potent, long-acting drug and that the incidence of nausea and vomiting following its administration is very low. In this series of 60 cases piritramide 15 mg was compared with morphine 10 mg in a double-blind trial. The drug was found to have a potency similar to that of morphine and a mean duration of action of greater than 6½ hours (morphine 4 ½ hours). The incidence of nausea and vomiting was low with both drugs and piritramide appeared to exert a slight anti-emetic effect.


1987 ◽  
Vol 151 (2) ◽  
pp. 152-155 ◽  
Author(s):  
K. R. Abraham ◽  
P. Kulhara

The efficacy of ECT was investigated in a double-blind trial. Twenty-two patients with schizophrenia received trifluoperazine and were randomly allocated to receive eight real or eight simulated ECTs. In the first eight weeks, the group receiving real ECTs showed significantly more improvement as measured on the Brief Psychiatric Rating Scale. However, the groups showed no significant differences from the twelfth week onwards. The superiority of real ECT was not confirmed at the end of six months.


PLoS ONE ◽  
2020 ◽  
Vol 15 (1) ◽  
pp. e0227490
Author(s):  
Nathalia Gouveia de Araujo Ferreira ◽  
Ismar Lima Cavalcanti ◽  
Alexandra Rezende Assad ◽  
Louis Barrucand ◽  
Estêvão Luiz Carvalho Braga ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document